Updated Oct 9, 2026 · 05:00 UTC
NBIXNeurocrine Biosciences, Inc.
Health Care · United States · XNAS · biological products, (no diagnostic substances)
$143.91−1.55%last session · market closed
Market cap
$14.63b
real-world
Tokenized
$26
<0.001% of the asset
Avg token price
$150.37
Spot volume, 24h
—
Derivatives, 24h
—
Perp open interest
—
In DeFi
—
NBIX · Price
Apr 28, 2025low $106.26 · high $184.34 · now $142.88Oct 8, 2026
Earnings
Nasdaq’s earnings calendar
Next earnings
Oct 27
estimated date · Sep 2026 quarter · EPS forecast $1.99 (7 analysts)
Last earnings, Jul 30
$2.36 EPS
+25.5% vs $1.88 forecast · Jun 2026 quarter
Real market
Neurocrine Biosciences Inc
Last close
$143.47
Oct 7
Traded on Oct 7
$164.9m
Price now
$143.91
market closed
Where it trades
24h volume by venue, as the exchanges report it · open interest and funding on the perpetuals
Spot · — · 0 venues
None yet
Derivatives · — · 0 venues
None yet
Onchain versions
1 token from 1 issuer
wNBIXxBacked Assets——By chain
Where the tokens circulate, issuers’ unsold stock taken off
In DeFi
Pools and lending markets that hold these tokens
None found
Business 12 months to Jun 2026 · SEC EDGAR
Results
Revenue
$3.37b
+34% YoY
Operating income
$794.8m
24% margin · +61% YoY
Net income
$705.5m
21% margin · +103% YoY
EPS, diluted
$6.77
+96% YoY
Cash and balance sheet
Free cash flow
$870.4m
26% of revenue
Cash and securities
$481.7m
debt not tagged
Diluted shares
104m
+3% YoY
Valuation at today’s market cap
P/E
21×
P/S
4.3×
Free cash flow yield
6.0%
Quarterly
RevenueNet income